Impact of glycemic control on advanced glycation and inflammation in overweight and obese patients with type 2 diabetes mellitus

Kalninova J1, Jakus V1, Glejtkova M2, Kuracka L1, Sandorova E1

Institute of Medical Chemistry, Biochemistry and Clinical Biochemistry, Faculty of Medicine, Comenius University, Bratislava, Slovakia. jana.kalninova@fmed.uniba.sk

Abstract: Aim: In this study we tried to investigate the impact of glycemic control on parameters of glycation and inflammation in overweight and obese patients with type 2 diabetes mellitus.

Patients and methods: Markers of glycation (HbA1c, AGEs; measured by HPLC and spectrofluorimetry, resp.) and inflammatory markers (IL-6, IL-8, TNF-α, MCP-1; measured by xMAP technology) were assessed in 69 patients with T2DM, of whom 32 were patients were with poor glycemic control (PGC group), 37 patients were with good glycemic control (GGC group) and 23 were healthy blood volunteers.

Results: Our results showed that plasma levels of fluorescent AGEs, IL-6, IL-8, TNF-α, and MCP-1 were significantly increased in PGC and GGC groups in comparison with control group, while the levels were higher in PGC group in comparison with GGC group, but the difference was not significant. We found a positive correlation between AGEs and MCP-1 and between TNF-α and creatinine in PGC group. We found significantly decreased levels of glycated HbA1c and AGEs in patients who used statins compared to patients who used fibrates. We observed beneficial impact of treatment with oral antidiabetic (OAD) agents + insulin on levels of IL-8, TNF-α and TAG in comparison with treatment with insulin alone.

Conclusions: Despite good glycemic compensation of patients with T2DM, levels of AGEs and inflammatory markers remained significantly elevated in comparison with healthy controls. There was a beneficial impact of treatment with OAD agents + insulin in sense of lowering the low-grade inflammation (Tab. 3, Fig. 7, Ref. 113). Text in PDF www.elis.sk.

Key words: glycemic control, overweight, obesity, diabetes mellitus, inflammation,


Many chronic diseases are now in pandemic proportions and increasingly becoming the major cause of morbidity and mortality worldwide. Diabetes mellitus, especially type 2 diabetes mellitus (T2DM), plays a starring role in this problem, with diabetic complications being a very important public health issue (Beaglehole and Yach, 2003). Diabetes mellitus is a metabolic disorder which is characterized by hyperglycemia and glucose intolerance due to insulin deficiency, impaired effectiveness of insulin action, or both. Diabetes mellitus, especially T2DM, is a public health problem which has reached epidemic proportions due the rapidly increasing rates of this disease worldwide. Target organ complications secondary to diabetes will be one of the most important medical concerns in the coming decades (Navarro and Mora, 2005).
Hyperglycemia is a common feature of diabetes mellitus, and the main pathogenic factor of diabetes and vascular (Hegab et al. 2012) and other complications (Miller et al., 1996; Korpáš and Jakuš, 2000). Hyperglycemia was shown to act deleteriously through a number of pathways, including the aldose reduction pathway, advanced glycation end product (AGE) pathway, reactive oxygen intermediate pathway, and PKC pathway (King, 2008). Hyperglycemia also induces both postprandial and chronic low-grade inflammation (Calder et al, 2011). Long-term hyperglycemia is linked with glycation, glycoxidation, oxidative stress, and inflammation (Aronson, 2008; Negre-Salvayre et al, 2009). The degree of glycation of hemoglobin provides information about the glucose level (quality of diabetes control) over previous 6–8 weeks (Racz et al, 1989).

Advanced glycation end products (AGEs) are considered to be a heterogeneous group of compounds that arise non-enzymatically by the reaction of reducing sugars and other α-carbonyl compounds with amino groups, not only with proteins but also with lipids and nucleic acids. Schiff’s base, which results from condensation of glucose with a lysine residue on a protein, typically undergoes a so-called Amadori rearrangement resulting in fructosamine (ketosamine) structure. This is the reason why one of the best known Amadori products, HbA1c, adduct of hemoglobin and glucose, can be used as a major indicator for hyperglycemia. Further rearrangements, oxidations and eliminations are needed to finally form the members of the highly heterogenous group of AGEs (Nass and Simm, 2009).

AGEs have a pathogenic importance in diabetes (Sebekova and Somoza, 2007). The formation of AGEs is an important biochemical abnormality that accompanies diabetes mellitus and likely also inflammation in general (Basta et al, 2003). AGEs induce cross-linking processes in the structure of long-lived proteins such as collagen. By binding to their specific receptor, they activate intracellular signalling pathways which lead to cytokine production, responsible for proinflammatory and prothrombotic effects (Inagaki et al, 2003).

AGEs detectable in vivo include three main groups; (1) Fluorescent cross-linking AGEs such as pentosidine and crossline; (2) Non-fluorescent cross-linking AGEs such as imidazoloid dialysine cross-links named either glyoxal lysine dimer or methylglyoxal lysine dimer result from reactions taking place between glyoxal derivatives and lysine residues; (3) Non-cross-linking AGEs such as N-carboxymethyllysine (CML) (Hegab et al, 2012). The formation of AGEs is suppressed by intensive glycemic control and may be suppressed in future by thiamine and pyridoxamine supplementation and several other pharmacological agents. However, when complications are already present, the improvement in glycemic control alone does not have to be sufficient to prevent the continued progression of these pathological processes, potentially due to irreversibility of AGEs deposits formation, and poor clearance mechanisms (Hatfield, 2005). AGEs interact with certain receptors such as that for AGE (RAGE) to induce intracellular signalling that leads to enhanced oxidative stress and elaboration of key proinflammatory and prothrombotic cytokines (Goh and Cooper, 2008). AGE receptor RAGE is a multiligand member of the immunoglobulin superfamily of cell surface molecules. AGE-receptor interaction can alter the functions of macrophages, and endothelial, mesangial and mesothelial cells, and can induce inflammation. Oxidative stress, vascular permeability, vascular cell adhesion molecule-1 (VCAM-1) overexpression, and monocyte chemotactarctant protein-1 (MCP-1) production have been observed after cell activation by AGEs. AGEs appear to be involved in the genesis of diabetic macro- but also microangiopathy such as retinopathy and glomerulosclerosis (Boulanger et al, 2006). The AGE/RAGE interaction activates a series of intracellular signalling pathways, including nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and nuclear factor kappa-B (NFκB), with production of reactive oxygen species (ROS) (Wautier et al, 2001). The cellular response can involve several types of processes – proinflammatory, profibrotic, procoagulant and/or angiogenic – with overexpression of cell adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1), and production of cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), tissue factor and vascular endothelial growth factor (VEGF) (Schmidt et al, 2001; Boulanger et al, 2002; Wautier and Schmidt, 2004; Boulanger et al, 2007).

Activation of inflammatory processes may contribute to the development of T2DM. In addition, inflammation appears to be a major mechanism responsible for vascular damage leading to the clinically well-recognized complications of diabetes. Activation of growth factors and adhesion molecules may promote the movement of inflammatory cells into the renal microvasculature, thus predisposing to the development of diabetic nephropathy. Emerging evidence also indicates that markers of inflammation are associated with the more severe forms of diabetic retinopathy (Williams and Nadler, 2007). Inflammation is considered to be a key regulator of the pathogenesis of T2DM, but what triggers this inflammation is still unknown (Pickup and Crook, 1998). However, it may be related to obesity. Obesity is associated with enlargement of adipose tissue, and consequently increases the number of adipose tissue macrophages (Cinti et al, 2005; Goyal et al, 2012). These macrophages are responsible for almost all adipose tissue TNF-α expression, significant amounts of IL-6, and other acute-phase response markers and mediators of inflammation (Weisberg et al, 2003; Cinti et al, 2005; Popko et al, 2010). Low-grade inflammation is a characteristic feature of obese state. Obese people have higher circulating concentrations of many inflammatory markers than lean people do, and these are believed to play a role in causing insulin resistance and other metabolic disturbances (Calder et al, 2011). Obesity is associated with an increased risk of developing T2DM, fatty liver disease, hypertension and vascular complications (Williams and Nadler, 2007). Proinflammatory and anti-inflammatory bioactive molecules produced from adipose tissues contribute to the burden of obesity-related diseases (Donath and Shoelson, 2011). Adipose tissue consists of heterogeneous populations of adipocytes, stromal preadipocytes, immune cells, and vascular cells, and it can respond rapidly and dynamically to alterations in nutrient excess caused by enhanced food consumption through adipocyte hypertrophy and hyperplasia (Shoelson et al, 2006). This results in a local inflammation in adipose tissue that
pragmatates an overall systemic but chronic low-grade inflammation associated with the development of obesity-related comorbidities such as type 2 diabetes and cardiovascular diseases (Yamamoto and Yamamoto, 2013). The possibility that obesity, and the activation of adipose tissue in particular, may enhance the release of inflammatory factors that underlie the development of insulin resistance has generated intense interest in the field of diabetes for a number of reasons.

The TNF-family of cytokines plays an important role in regulating inflammation and apoptosis. The first cytokine discovered is TNF-α, which is produced by neutrophils, macrophages, and adipocytes and can induce other powerful cytokines such as IL-6, which in turn regulates the expression of C-reactive protein (CRP). CRP increases the expression of endothelial ICAM-1, VCAM-1, E-selectin and MCP-1 (Pasceri at al, 2000; Venugopal et al, 2002). The proinflammatory cytokines IL-1β, IL-6, and TNF-α have cytotoxic, cytostatic (inhibition of insulin synthesis and secretion), or cytocidal actions to pancreatic islets by inducing nitric oxide production (Rapport et al, 1998; Erbacci et al, 2001; Tchorzewski et al, 2001). Chemokines have a role in inflammation (Buc and Bucova, 2000). Elevated plasma free fatty acids (FFA), leptin, resistin, TNF-α and IL-6 concentrations have been reported in obese subjects (Bastard et al, 2006; Hajer et al, 2008; Rasouli and Kern, 2008). Previous studies suggested that low-grade systemic inflammation plays a role in pathogenesis of some glucose disorders in adults (prediabetic state) (Pickup and Crook, 1998). Several cross-sectional studies showed that insulin resistance and type 2 diabetes are associated with higher levels of C-reactive protein (CRP), IL-6, and TNF-α (Nilsson et al, 1998; Yudkin et al, 1999; Ford, 1999; Festa et al, 2000; Frohlich et al, 2000; Temelkova-Kurktschiev et al, 2002). Furthermore, various longitudinal studies have shown that elevated levels of IL-6 predict the development of T2DM (Pradhan et al, 2001; Freeman et al, 2002; Festa et al, 2002).

The aim of our study was to evaluate the impact of glycation control on glycation (HbA1c, AGEs) and inflammation (IL-6, IL-8, TNF-α, MCP-1) in overweight and obese patients with T2DM.

Patients and methods

Study patients and design

The study was approved by our local ethics committee and every subject accepted to participate by signing a written informed consent.

Plasma was obtained after 12 hours of overnight fasting from 23 healthy control subjects and 69 overweight and obese patients with T2DM. Plasma was obtained from 2nd Internal Medicine Clinic, University Hospital, Mickiewiczova, Bratislava. Plasma was stored frozen at −70 °C.

Exclusion criteria were pregnancy or lactation, cancer, mental health problems, and secondary diabetes. All T2DM patients were divided into 2 groups according to the value of glycated hemoglobin (HbA1c). The patients with HbA1c ≤ 6 % had good glycemic control (GGC group, n = 37) and those with HbA1c > 6% had poor glycemic control (PGC group, n = 32) regardless of presence of diabetic complications.

Sixteen patients used oral antidiabetic (OAD) agents, 7 patients used OAD agents and had diet, 5 patients were treated with a combination of insulin and OAD agents (I+OAD), and 6 patients were treated with insulin alone. Twenty patients received lipid or cholesterol lowering drugs (16 statins, 4 fibrates). Forty-four patients were without diabetic complications (NC), 13 patients had microvascular complications (micro VC) and 8 patients had in addition to micro VC also macrovascular complications (micro+macro VC).

Clinical and anthropometric assessment

Resting blood pressure levels were measured in the left arm in a sitting position by sphygmomanometer (Omron M3, Intellisense, Japan). Body weight and height were measured without shoes and with light clothing using a digital weighing and measuring station with automatic body mass index (BMI) calculation (kg/m², SECA 764, Germany). Overweight was defined by BMI > 25 ≤ 30 and obesity by BMI > 30. Waist circumferences were measured in centimeters with an inelastic tape to the nearest millimeter with the subject in a standing position.

Determination of basic biochemical parameters

Fasting blood glucose (FBG) was measured by glucose oxidase method using Hitachi 911 Analyser (Roche Diagnostic, Switzerland).

Serum total cholesterol (TC), high density cholesterol (HDL-C), low density cholesterol (LDL-C) and triacylglycerols (TAG) were evaluated enzymatically and colorimetrically using automatic analyser Cobas Integra 400 (Roche, Switzerland). Serum creatinine was estimated using enzymatic method (Vitro 250, Johnson and Johnson Company, USA).

Analyses of creatinine (CRT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyltransferase (GMT), albumin (ALB) and bilirubin (BIL) were assessed by standard methods as part of routine examination of patients at 2nd Internal Medicine Clinic, University Hospital, Mickiewiczova, Bratislava, Slovakia.

Determination of HbA1c and advanced glycation

HbA1c was measured by HPLC (DiaSTAT, Bio-RAD, USA) using the IFCC calibration. Determination of AGEs (i.e., some fluorescent products from the family of AGEs) was based on the spectrofluorimetric detection according to Henle et al (1999) and Münch et al (1997) in modification by Kalousová et al (2001).

Blood plasma was diluted 1:50 with PBS pH 7.4 and fluorescence intensity was recorded at the emission maximum at 445 nm upon excitation at 370 nm (spectrofluorimeter Perkin Elmer LS 45). Fluorescence intensity was expressed in arbitrary units (AU)/g protein.

Determination of inflammatory markers

Plasma levels of IL-6, IL-8, TNF-α and MCP-1 were determined using Fluorokine MAP cytokine multiplex kit designed for use with Athena Multi-Lyte Lumineux® 100™ analyser produced at R&D Systems (Minneapolis, MN, USA) according to the manufacturer’s instructions. The cytokines were analysed using xMAP™ technology which combines the principle of sandwich.
immunoassay with fluorescent-bead-based technology allowing multiplex analysis of up to 100 different analytes in a single microtiter well.

Statistical analysis

For statistical analysis we used softwares Origin 8 and Excel 2010. Normality of data distribution was found out using Shapiro-Wilk test. Extremely different data were excluded from further calculations. When all groups of data of given parameter were Gauss’ distributed, we compared them using ANOVA 1 factor without repetition and Bonferroni post-hoc test for evaluation of significant differences between pairs. For graphical expression we used column diagrams and values were expressed as means ± standard deviation (SD). If one of compared data files did not demonstrate normal distribution, we used Kruskal–Wallis test and the next Bonferroni test. In case of two data files we used Mann–Whitney nonparametric test. Graphical expression was carried out using Box-plot diagrams, and results were expressed as median (1st, 3rd quartile). The correlation between the measured parameters was examined using the Pearson’s correlation test or by the Sperman’s rank correlation test (r, p). P value less than 0.05 was considered statistically significant.

Results

Comparison of baseline and biochemical parameters

Baseline characteristics of subjects

Baseline characteristics of subjects are shown in Table 1. We observed significantly higher waist circumference (WC) and systolic blood pressure (SBP) in PGC and GGC group in comparison with control group. There were no differences in body mass index (BMI) and diastolic blood pressure (DBP) in PGC and GGC groups in comparison with control group.

Biochemical parameters of subjects

Biochemical parameters of subjects are shown in Table 2. Biochemical evaluation revealed a significantly higher fasting glucose (FBG) and TAG in PGC and GGC group in comparison with control group. HDL-C was significantly lower in PGC and GGC group in comparison with control group.

Parameters of advanced glycation and inflammation of subjects

Parameters of advanced glycation and inflammation are shown in Table 3. We found significantly increased plasma levels of AGEs (Fig. 1), TNF-α (Fig. 2), IL-6 (Fig. 3), IL-8 (Fig. 4), and MCP-1 with control group. There were no differences in body mass index (BMI) and diastolic blood pressure (DBP) in PGC and GGC groups in comparison with control group.

Tab. 1. Baseline characteristics of subjects.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>PGC group</th>
<th>GGC group</th>
<th>CTRL group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>63.00 (58.50 – 68.50)*</td>
<td>62.00 (57.00 – 70.00)*</td>
<td>49.00 (40.50 – 58.00)</td>
</tr>
<tr>
<td>DD (years)</td>
<td>14.00 ± 8.10</td>
<td>11.00 ± 7.0</td>
<td>-</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>28.9 (27.3 – 31.3)</td>
<td>28.2 (27.2 – 32.2)</td>
<td>25 (22.70 – 32.40)</td>
</tr>
<tr>
<td>WC (cm)</td>
<td>102 (96 – 109) *</td>
<td>102 (97 – 108) *</td>
<td>90 (83.00 – 100.00)</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>148 (130 – 158) *</td>
<td>142 (131 – 156) *</td>
<td>120 (120.00 – 130.00)</td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>81 (74 – 85)</td>
<td>78 (73 – 83)</td>
<td>80 (80.00 – 80.00)</td>
</tr>
</tbody>
</table>

Data are presented as means ± standard deviation in data with normal distribution and as median (1st quartile – 3rd quartile) in data with non-normal distribution, * Significant difference in comparison with control group.

Tab. 2. Biochemical parameters of subjects.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>PGC group</th>
<th>GGC group</th>
<th>CTRL group</th>
</tr>
</thead>
<tbody>
<tr>
<td>FBG (mmol/l)</td>
<td>9.90 ± 2.90*</td>
<td>8.10 ± 2.70*</td>
<td>5.20±0.40</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>7.43 ± 0.82*</td>
<td>5.02 ± 0.71*</td>
<td>5.16 ± 0.42</td>
</tr>
<tr>
<td>TC (mmol/l)</td>
<td>5.16 ± 1.10</td>
<td>4.55 ± 0.90</td>
<td>4.97 ± 1.20</td>
</tr>
<tr>
<td>TAG (mmol/l)</td>
<td>1.57 (1.2 – 2.2) *</td>
<td>1.4 (0.98 – 2.33) *</td>
<td>1.22 (0.96 – 1.75)</td>
</tr>
<tr>
<td>HDL-C (mmol/l)</td>
<td>1.25 ± 0.30*</td>
<td>1.21 ± 0.30*</td>
<td>1.44 ± 0.30</td>
</tr>
<tr>
<td>LDL-C (mmol/l)</td>
<td>2.90 ± 0.80</td>
<td>2.49 ± 0.70</td>
<td>2.84 ± 1.00</td>
</tr>
<tr>
<td>ALT (μkat/l)</td>
<td>0.67 (0.42 – 0.99)</td>
<td>0.46 (0.37 – 0.59)</td>
<td>0.51 (0.32 – 0.79)</td>
</tr>
<tr>
<td>AST (μkat/l)</td>
<td>0.40 (0.32 – 0.51)</td>
<td>0.39 (0.33 – 0.54)</td>
<td>0.43 (0.38 – 0.58)</td>
</tr>
<tr>
<td>GMT (μkat/l)</td>
<td>0.60 (0.30 – 1.15)</td>
<td>0.44 (0.31 – 0.67)</td>
<td>0.52 (0.36 – 0.84)</td>
</tr>
<tr>
<td>BIL (μmol/l)</td>
<td>8.50 (5.60 – 15.10)</td>
<td>6.8 (5.70 – 9.15)</td>
<td>8.00 (6.4 – 11.70)</td>
</tr>
<tr>
<td>ALB (g/l)</td>
<td>45.00 ± 2.60</td>
<td>44.00 ± 1.60</td>
<td>44.00 ± 5.10</td>
</tr>
<tr>
<td>CRT (μmol/l)</td>
<td>77.00 ± 15.40</td>
<td>76.00 ± 18.00</td>
<td>72.00 ± 18.90</td>
</tr>
</tbody>
</table>

Data are presented as means ± standard deviation in data with normal distribution and as median (1st quartile – 3rd quartile) in data with non-normal distribution, * Significant difference in comparison with control group, + significant difference between PGC and GGC group.
Kalninova J et al. Impact of glycemic control on advanced glycation and inflammation...

Correlations between measured parameters

**Correlations of markers of advanced glycation and inflammation of subjects with baseline parameters**

In PGC and GGC groups we did not find any correlations of measured parameters. In control group we found a significantly positive correlation of AGEs with age \( r = 0.424, p = 0.031 \). There was found a significantly negative correlation of IL-6 and IL-8 with DBP \( r = -0.470, p = 0.027 \), respectively; \( r = -0.707, p < 0.0001 \).

There was found also a significantly negative correlation between TNF-\( \alpha \) and age \( r = -0.461, p = 0.020 \).

**Correlations of markers of advanced glycation and inflammation of subjects with biochemical parameters**

In PGC group we found a significantly positive correlation between AGEs and HDL \( r = 0.511, p = 0.011 \), significantly positive correlation between AGEs and MCP-1 \( r = 0.659, p < 0.0001 \) (Fig. 6), and significantly negative correlation between AGEs and TNF-\( \alpha \) \( r = -0.468, p = 0.018 \). IL-6 was significantly positively correlated with creatinine \( r = 0.625, p = 0.002 \) (Fig. 7). There was a significantly negative correlation between IL-8 and albumin \( r = -0.793, p = 0.033 \) and significantly positive correlation...
between IL-8 and MCP-1 ($r = 0.624$, $p = 0.0001$). We found a significantly negative correlation between TNF-α and MCP-1 ($r = -0.499$, $p = 0.007$).

In control group we found a significantly negative correlation between AGEs and IL-6 ($r = -0.470$, $p = 0.004$). We found a significantly negative correlation between IL-6 and TC ($r = -0.479$, $p = 0.015$) and LDL ($r = -0.579$, $p = 0.007$). We found a significantly positive correlation between IL-8 and TNF-α ($r = 0.751$, $p < 0.0001$) and between IL-8 and MCP-1 ($r = 0.584$, $p = 0.004$). There was found a significantly negative correlation between IL-8 and LDL ($r = -0.489$, $p = 0.046$) and a significantly positive correlation between IL-8 and TNF-α ($r = 0.744$, $p < 0.0001$). Besides that, TNF-α was significantly negatively correlated with LDL ($r = -0.510$, $p = 0.031$) and significantly positively correlated with MCP-1 ($r = 0.629$, $p = 0.002$).

**Effect of treatment**

We observed the effect of treatment in patients who used OAD agents ($n = 16$), OAD agents and had diet ($n = 7$), as well as in patients who were treated with a combination of insulin and OAD agents ($n = 5$) and patients who were treated with insulin alone ($n = 6$).

The patients who were treated by insulin had significantly increased levels of IL-8 compared to patients treated with OAD agents 7.52 (5.40–7.84) pg/ml vs 3.96 (3.04–4.92) pg/ml ($p = 0.004$). We observed increased levels of IL-8 in patients who were treated by insulin compared to patients treated with OAD agents + insulin 7.52 (5.40–7.84) pg/ml vs 3.96 (3.04–5.24) pg/ml ($p = 0.018$). Patients who used OAD agents + insulin had the same significantly decreased levels of TNF-α compared to patients who were treated with insulin 4.52 (4.08–4.96) pg/ml vs 5.60 (5.50–5.84) pg/ml ($p = 0.004$, resp. $0.026$). Patients who used OAD agents + had diet had significantly decreased levels of TNF-α compared to patients who were treated with insulin 4.08 (4.08–4.52) pg/ml vs 5.60 (5.50–5.84) pg/ml ($p = 0.009$). Patients who used OAD agents had significantly decreased levels of TAG compared to patients who were treated with OAD agents + insulin 2.10 (1.32–2.55) mmol/l vs 1.22 (0.98–1.47) mmol/l ($p = 0.002$). Our results showed that patients who used OAD agents had significantly decreased levels of AST compared to patients treated by OAD agents + insulin 0.53 (0.44–0.60) μkat/l vs 1.22 (0.98–1.47) μkat/l ($p = 0.045$) and compared to patients treated by OAD agents + diet 0.53 (0.44–0.60) μkat/l vs 0.33 (0.32–0.36) μkat/l ($p = 0.030$). TAGs were significantly decreased in patients who used OAD agents compared with patients who were treated with OAD agents + insulin 2.10 (1.32–2.55) mmol/l vs 1.22 (0.98–1.47) mmol/l ($p = 0.002$). Twenty patients had received lipid or cholesterol lowering drugs (16 statins, 4 fibrates). We found significantly decreased levels of HbA1c in patients who used statins compared to patients who used fibrates ($p = 0.015$). We found significantly decreased levels of AGEs in patients who used statins compared to patients who used fibrates ($p = 0.050$).

**Discussion**

The preclinical and clinical studies of the past years demonstrated a close participation of AGEs in all of the micro- and macrovascular complications of diabetes, especially in T2DM (Chilelli et al, 2013).

In our study, we found significantly elevated plasma levels of AGEs in poor and good glycemic compensation groups of overweight and obese patients in comparison with healthy control group.


In contrast to our findings there is the study of Wagner et al (2001) who demonstrated normal levels of fluorescent AGEs also...
in patients with T2DM who had normal renal function. In patients with T2DM the concentration of AGEs seems to be mainly influenced by the quality of diabetes control (Hatfield, 2005). Intensive glycemic control in patients from DCCT trial led to a lower risk of diabetic microvascular complications compared to conventional treatment. The lower risk was associated with lower AGE levels, even after adjustment for Hba1c (DCCT, 1993). The importance of glycemic control was also confirmed by our results. We believe that good glycemic control is an important part of prevention of developing pathological processes due to the irreversibility of AGE formation, and poor clearance mechanisms.

In their study, Gottsäter et al (2004) evaluated s-AGEs in T2DM patients at baseline and at follow up three years later. They revealed significantly increased levels of AGEs. They revealed that AGEs correlated significantly with plasma cholesterol, both at baseline and at follow up, plasma HDL cholesterol at baseline and with plasma LDL cholesterol at follow up. In addition, plasma LDL cholesterol at baseline correlated with AGEs at follow up. However, there were no significant correlations between Hba1c and AGEs.

Significantly higher AGE levels in diabetics compared to non-diabetics on regular hemodialysis treatment both before and after dialysis session were revealed by Kalousová et al (2003). In this study AGEs did not correlate with parameters of glucose metabolism correction (FBG, Hba1c).

In the study of Makita et al (1991), the mean AGE content of samples of diabetic patients was significantly higher than that of samples from nondiabetic patients. Gul et al (2009) found serum AGEs level significantly lower in control group in contrast to senile diabetic patients. Serum low-molecular weight AGEs were significantly higher in diabetics compared to non-diabetic subjects in the study of Sharp et al (2003). The serum levels of AGEs were higher in diabetic subjects without complications compared with nondiabetic subjects, higher among diabetic subjects with retinopathy and highest in diabetic subjects with both retinopathy and nephropathy in the study of Sampathkumar et al (2005). Sampathkumar et al (2005) found a significantly positive correlation between AGEs and glycated hemoglobin, cholesterol and triacylglycerols.

Mirza et al (2012) estimated that fluorescent AGEs correlated inversely with the magnitude of each complication. For instance, serum AGEs were significantly lower in patients without retinopathy versus mild, moderate or severe retinopathy and lower, but not significantly, in patients without peripheral neuropathy versus mild, moderate or severe peripheral neuropathy. In the study of Sharp et al (2003) there was no correlation between serum LMW-AGEs and Hba1c.

In contrast, Shimoike et al (2000) estimated that serum AGE levels in diabetic patients were not significantly higher than those in normal subjects.

In our study, we found out that plasma levels of proinflammatory markers IL-6, IL-8, TNF-α and MCP-1 were elevated in PGC and GGC overweight and obese patients. In agreement with our findings Barbarroja et al (2012) found increased TNF-α and IL-6 in obese people with type 2 diabetes. Czyzewska et al (2012) in their study divided the patients into three groups: group I – patients with type 2 diabetes with Hba1c ≥ 6.1 – ≤ 6.5 %, group II – patients with type 2 diabetes with Hba1c > 6.5 – ≤ 10.0 %, K – control group. The average concentration of IL-6 was highest in group I, lower in group II, and lowest in control group. Several cross-sectional studies showed that type 2 diabetes is associated with higher levels of TNF-α and IL-6 (Nilsson et al, 1998; Yudkin et al, 1999; Festa et al, 2000; Temelkova-Kurtchiesev et al, 2002). Marques-Vidal et al (2013) in their study found that participants with diabetes had higher IL-6 and TNF-α levels than participants without diabetes. According to Tönjes et al (2010), fasting serum TNF-α and fasting serum IL-6 levels were not significantly different among the groups in any of the prediabetic group compared to controls.

In contrast, Festa et al (2002) showed decreased levels of TNF-α and IL-6 in T2DM compared to healthy controls. Decreased levels of inflammatory cytokines in their study were in disagreement with next findings. A recent study by Marques-Vidal et al (2013) found that subjects with T2DM had increased levels of IL-6 and TNF-α. It was also reported, that high levels of inflammatory cytokines appear in early stages of type 2 diabetes mellitus and are capable of predicting the development of T2DM (Festa et al, 2002). In contrast to some of existing evidence, few studies found that no significant difference is seen in plasma TNF-α or IL-6 levels between obese and non-obese subjects (Tsigos et al, 1999).

Agarwal et al (2011) found that TNF-α levels in obese patients were higher than those in non-obese patients. However, the levels of IL-6 were higher in non-obese group. Ahmad et al (2012) found levels of TNF-α and IL-6 highly elevated in obese subjects compared to lean subjects. It has been demonstrated by many researches that serum levels of TNF-alpha are elevated in obesity (Zahorska-Markiewicz et al, 2000; Laimer et al, 2002). TNF-alpha is involved in the pathophysiology of obesity-associated insulin resistance and atherosclerosis (Nieto-Vasquez et al, 2008; Yudkin, 2007). Tsigos et al (1999) showed that there is no significant difference in plasma TNF-α levels between obese and non-obese subjects.

Plasma levels of TNF-α and IL-6 were moderately correlated in study of Rekeneire et al (2006). The correlation between TNF-α and IL-6 was 0.19 (p < 0.0001). Levels of TNF-α and IL-6 were significantly higher in diabetic group compared with the non-diabetic group. The association between diabetes and high level of inflammation remained even after adjustments for possible confounders such as demographics, lifestyle habits, total body fat, visceral fat, and comorbidities.

In agreement with our findings, the study of Chen et al (2003) found no correlation between fasting blood glucose and TNF-α and IL-6 levels in patients with T2DM.

We found a positive correlation between TNF-α and creatinine in PGC group. In agreement with our findings, TNF-α was positively correlated with creatinine (p < 0.001) in the study of Zietz et al (2000). Kaffe et al (2012) found correlation between creatinine and TNF-α and IL-6 in T2DM nephropathy subjects. In contrast, there was no correlation between TNF-α levels in the diabetes group and serum creatinine in the study of Spranger et al (1995).
Guzel et al (2012) and Yaseen et al (2012) observed a significantly elevated IL-6 level in diabetic patients. The results of Pitsavos (2007) are consistent with the hypothesis that low-grade inflammation is closely involved in the pathogenesis of T2DM. It has been demonstrated in various studies that circulating IL-6 levels are elevated in T2DM (Muller et al, 2002; Tönjes et al, 2010). According to the study of Marques-Vidal et al (2012), the subjects who developed T2DM had significantly higher baseline level of IL-6 than subjects who remained free of T2DM.

Various studies have demonstrated that circulating IL-6 levels are elevated in insulin resistant states such as impaired glucose tolerance and T2DM (Tönjes et al, 2010).

In contrast, serum levels of IL-6 were not significantly elevated in the diabetic group compared to the non-diabetic group (Andriankaja et al, 2009). IL-6 was found to be decreased in T2DM patients compared to normal controls (Al-Shukaili et al, 2013).

Gul et al (2013) have found elevations in levels of IL-8, IL-6 and TNF-α in diabetic patients with myocardial infarction as compared with non-diabetic patients with myocardial infarction and control subjects. Mirza et al (2012) found that IL-8, TNF-α and IL-6, when stratified on the basis of HbA1c values, were most significantly elevated in the group with HbA1c values > 6.5 % of Mexican Americans.

The mean serum TNF-α and IL-8 levels increased with the stage of diabetic retinopathy, and the highest levels were found in patients with proliferative diabetic retinopathy (PDR). The PDR patients had significantly higher serum IL-8 and TNF-α levels compared with non-proliferative (NPDR) patients, no DR (NDR) patients and controls. Serum levels of these parameters for NPDR patients were also significantly higher compared with those of NDR patients and controls. On the other hand, IL-8 and TNF-α levels of patients with NDR were comparable with those of controls (Doganay et al, 2002).

The diabetic patients had significantly higher concentrations of IL-8 and MCP-1. The IL-8 and MCP-1 levels in the aqueous humor increased as the severity of DR increased (Dong et al, 2013).

Diabetes is a heterozygous disorder and atherosclerosis is its risk factor. It has been almost proved that inflammation has an important role in atherosclerosis. Evidences show that chemokines such as IL-8 and MCP-1 have an important role in this process by attracting monocytes inside the arterial wall (Spranger et al, 2003). Monocytes are the primary inflammatory cells which are found in atherosclerotic plaques (Shin et al, 2002). Apart from their role in inflammation, chemokines are involved also in other biological activities as angiogenesis, hematopoiesis, as well as in enhancing the host response to tumors (Buc and Bucova, 2000). IL-8 mediates the binding of glucose-stimulated monocytes to the endothelium and it has been shown that it is involved in plaque formation of atherosclerosis disease. Therefore, the high incidence of heart disease and atherosclerosis in T2DM patients may be due to IL-8 (Siminini et al, 2000).

Circulating MCP-1 has been found significantly increased in patients with T2DM (Piemonti et al, 2009). The plasma level of MCP-1 has been generally found increased in obese children (Breslin et al, 2012). Wakabayashi et al (2011) have found that IL-8 and MCP-1 concentrations in samples from diabetic patients were significantly higher than the concentrations for nondiabetic controls, and the aqueous humor levels of IL-8 and MCP-1 were closely correlated with the severity of DR (Petrovic et al, 2007; Praidou et al, 2009; Liu et al, 2010; Cheung et al, 2012).

We found a positive correlation between AGEs and MCP-1 in PGC group. Some other studies showed an association between AGEs and induction of expression of MCP-1 (Yamagishi et al, 2002; Gu et al, 2006). Enhanced generation of AGEs stimulated the secretion of MCP-1 either alone, or synergistically combined with high concentrations of glucose (Banba et al, 2000; Schacky et al, 2001).

Conclusions

The obtained results showed that in order to recognize the risk of diabetic complications it may be useful to monitor the parameters of fluorescent advanced glycation and low-grade inflammation especially in patients with poor glycemic control. The fluorimetric assay is advantageous because this method is simple, time saving and not expensive.

Despite good glycemic compensation in patients with T2DM, the levels of AGEs and inflammatory markers remained significantly elevated in comparison with healthy controls.

We found significantly decreased levels of HbA1c andAGEs in patients who used statins compared to patients who used fibrates. We observed a beneficial impact of treatment with OAD agents + insulin on levels of IL-8, TNF-α and TAG in comparison with treatment with insulin alone.

References


12. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006; 17: 4–12.


Received February 21, 2014.
Accepted April 18, 2014.